ImmunityBio COVID-19 vaccine

First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity

Retrieved on: 
Tuesday, November 7, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Genetics, MHC, Neoplasm, SCLC, NCI, NE, Society for Immunotherapy of Cancer, Medicine, Carcinoma, Cell, Glomus tumor, SITC, Immunotherapy, Small-cell carcinoma, NK, Cancer, Society, ICB, Patient, Abstract, Bangladesh Technical Education Board, Pharmaceutical industry, Medical imaging, ImmunityBio COVID-19 vaccine

Small cell lung cancer (SCLC) is an aggressive neuroendocrine (NE) carcinoma and has few treatment options.

Key Points: 
  • Small cell lung cancer (SCLC) is an aggressive neuroendocrine (NE) carcinoma and has few treatment options.
  • In the new study, the killing capacity of M-ceNK cells was assessed in four SCLC cell lines representing the major molecular subtypes.
  • The M-ceNK cells were highly cytotoxic against all types of SCLC models, as well as against prostate neuroendocrine cancer.
  • “We are encouraged by the data coming out of this study and we look forward to assessing the potential for M-ceNK therapy in other tumor types.”

FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date

Retrieved on: 
Thursday, October 26, 2023
Oncology, Health, FDA, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, CIS, PDUFA, Food, Medicine, Safety, Bladder cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Maintenance, Immune system, NK, BCG, NMIBC, Patient, BLA, Pharmaceutical industry, Vaccine, Agency, ImmunityBio COVID-19 vaccine

The FDA has set a user fee goal date (PDUFA date) of April 23, 2024.

Key Points: 
  • The FDA has set a user fee goal date (PDUFA date) of April 23, 2024.
  • “We are pleased that the FDA has accepted ImmunityBio’s resubmission of the BLA as a complete response, following our productive interactions leading up to the resubmission.
  • N-803 is a novel investigational IL-15 superagonist complex consisting of an IL-15 mutant (IL-15N72D) bound to an IL-15 receptor α/IgG1 Fc fusion protein.
  • Safety and efficacy have not been established by any Health Authority or Agency, including the FDA.

ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ

Retrieved on: 
Monday, October 23, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, CR, Survival, CIS, FDA, Patient, Bladder cancer, Food, E pluribus unum, Treatment, Vol, Safety, The New England Journal of Medicine, Pivotal trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Maintenance, Literature, Immune system, NK, Massachusetts Medical Society, NEJM, Probability, Case series, PMID, Cystectomy, BCG, NMIBC, BLA, Exception, Vaccine, ImmunityBio COVID-19 vaccine, Tolerability

The BLA is supported by the results of ImmunityBio’s studies in bladder cancer including the pivotal QUILT-3.032 study (NCT03022825), published in NEJM Evidence1 in November 2022.

Key Points: 
  • The BLA is supported by the results of ImmunityBio’s studies in bladder cancer including the pivotal QUILT-3.032 study (NCT03022825), published in NEJM Evidence1 in November 2022.
  • Of the nine subjects, two were deceased from causes other than bladder cancer and one was lost to follow-up.
  • Final clinical Results of Pivotal Trial of IL-15rαfc Superagonist N-803 with BCG in BCG-Unresponsive CIS and Papillary Non-Muscle Invasive Bladder Cancer (NMIBC).
  • Phase II/III Clinical Results of IL-15rαfc Superagonist N-803 with BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma in Situ (CIS) Patients.

Lifshitz Law PLLC Announces Investigations of ImmunityBio, Inc. (NASDAQ: IBRX), BioXcel Therapeutics, Inc. (NASDAQ: BTAI), Baxter International Inc. (NYSE: BAX)

Retrieved on: 
Sunday, October 1, 2023
GMP, Institutional review board, Face, Telephone, CMOS, Record, Dementia, Patient, Advertising, BAX, FDA, ImmunityBio COVID-19 vaccine, Agitation, Hewlett, Safety, Online shopping

NEW YORK, Sept. 30, 2023 (GLOBE NEWSWIRE) --

Key Points: 
  • If you are an IBRX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • If you are a BTAI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516) 493-9780.
  • Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development

Retrieved on: 
Thursday, September 21, 2023
GMP, Hoffman, Amgen, Senior, Partner, Bayer, MBA, Georgetown University, Chemistry, Adenosine, Patient, Blue jay, Leukemia, Columbia University, Business development, BS, Cancer and Leukemia Group B, Infection, Leukemia & Lymphoma Society, MS, Corporation, Apple tree, Five-prime cap, Liver, NNRTI, Technology transfer, Roche, Business, Gilead Sciences, Amicus, Providence College, CMO, AbbVie, SAN, A2A, Amicus Therapeutics, Therapy, HBV, Catalant, SQZ, Model Business Corporation Act, HIV, Chiron Corporation, Hepatology, Oppenheimer, CMC, NDA, Hepatitis C, IND World's Fair Line, HCV, Management, Pharmaceutical industry, Genentech, ImmunityBio COVID-19 vaccine, Biotechnology, Searle

He will be a member of Bluejay’s Executive team, reporting to Keting Chu, Founder and CEO of Bluejay Therapeutics.

Key Points: 
  • He will be a member of Bluejay’s Executive team, reporting to Keting Chu, Founder and CEO of Bluejay Therapeutics.
  • “I am delighted to welcome Chris to the senior leadership team at Bluejay”, stated Mrs. Chu.
  • “Chris has an outstanding track record in business & corporate development with both public and private biotech and pharma companies.
  • Before joining Bluejay, he served as VP, Business & Corporate development at LEXEO Therapeutics, where he led all business development, strategic transactions and played a significant role in the company’s capital raising activities.

ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities

Retrieved on: 
Monday, September 11, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, Medicine, Therapy, NCV, Cancer, Bladder cancer, NK, NAnt, BCG, Patrick Soon-Shiong, Physician, Immune system, Security (finance), Pharmaceutical industry, ImmunityBio COVID-19 vaccine

The new $200 million convertible note with Nant Capital has a three-year term and is convertible into shares of ImmunityBio common stock at a conversion price of a fifty percent (50%) premium over the closing market price immediately preceding the date of the note.

Key Points: 
  • The new $200 million convertible note with Nant Capital has a three-year term and is convertible into shares of ImmunityBio common stock at a conversion price of a fifty percent (50%) premium over the closing market price immediately preceding the date of the note.
  • In addition, the financing transactions restructure the Company’s existing debt obligations with the Nant entities, including an extension of the nearest term debt maturities by one year to December 2024.
  • “With this additional financing, we are well positioned to execute on our commercialization plans in anticipation of the approval of N-803 plus BCG in bladder cancer.
  • We recognize the enormity of such a challenge and this investment will enable the scientists and physicians to pursue the goal of potentially curing cancer in our lifetime.”

Lifshitz Law PLLC Announces Investigations of Arrow Financial Corp. (NASDAQ: AROW), ImmunityBio, Inc. (NASDAQ: IBRX), BioXcel Therapeutics, Inc. (NASDAQ: BTAI), and Baxter International Inc. (NYSE: BAX)

Retrieved on: 
Sunday, September 3, 2023
GMP, Institutional review board, Face, Telephone, Disclosure, CMOS, Arrow, Record, Dementia, Patient, Advertising, Risk, BAX, FDA, ImmunityBio COVID-19 vaccine, Agitation, Hewlett, Safety, Pharmaceutical industry, Online shopping

If you are an AROW investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.

Key Points: 
  • If you are an AROW investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • If you are an IBRX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.
  • Prior results do not guarantee or predict a similar outcome with respect to any future matter.

IBRX DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important August 29 Deadline in Securities Class Action – IBRX

Retrieved on: 
Tuesday, August 29, 2023
Class Action Lawsuit, Professional Services, Legal, Titan, GMP, Good manufacturing practice, Class, CMOS, Advertising, Court, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, I-Space (Chinese company), Food, Insurance, Tobacco, ImmunityBio COVID-19 vaccine

WHAT TO DO NEXT: To join the ImmunityBio class action, go to https://rosenlegal.com/submit-form/?case_id=17455 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the ImmunityBio class action, go to https://rosenlegal.com/submit-form/?case_id=17455 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

IBRX FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages ImmunityBio (IBRX) Investors with Substantial Losses to Contact Firm’s Attorneys Before Aug. 29th Deadline in Securities Fraud Class Action

Retrieved on: 
Monday, August 28, 2023
GMP, Person, CMOS, Patient, Hagens Berman, SAN, FDA, BLA, News, Pharmaceutical industry, ImmunityBio COVID-19 vaccine

SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered substantial losses to submit your losses now .
  • ImmunityBio, Inc. (IBRX) Securities Fraud Class Action:
    The litigation focuses on ImmunityBio’s statements about the manufacturing and commercial prospects for its lead product candidate (Anktiva) for the treatment of patients with certain non-muscle invasive bladder cancer.
  • “We’re focused on investors’ losses and proving ImmunityBio misrepresented its GMP in light of the FDA’s findings,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in ImmunityBio and have substantial losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman .

DEADLINE ALERT for IBRX, BTAI, MNK, and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Monday, August 28, 2023
Acceleration, GMP, Institutional review board, BIS, Good manufacturing practice, Privacy Office of the U.S. Department of Homeland Security, Chapter 11, Title 11, United States Code, Software, CMOS, Trust, Record, Law, Complaint, Seagate, Suite, Dementia, Investment, Patient, Nature, Risk, Defendant, FDA, ImmunityBio COVID-19 vaccine, Science and technology in Asia, Agitation, Safety, Commerce, U.S. Department of Commerce Office of Security, Security (finance), Risk management, Mallinckrodt, Huawei

LOS ANGELES, Aug. 28, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Aug. 28, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • The Law Offices of Frank R. Cruz, Los Angeles